Good health for corporate investors

01/10/2013
Diego Gutiérrez
Good health for corporate investors

According to CBinsights data, the Novo Group tops the list of the most active corporate investors in the healthcare sector in terms of level of investment and number of deals. Johnson & Johnson and Novartis complete the top three.

1TP2Q1.81B of investment up 241TP1Q from previous quarter

Investment and exits in the healthcare sector made a strong comeback during 2Q13. Not only did capital invested and funded in healthcare companies reach 1.81B$ (up 24% from 1Q13) but investment in early stage companies also grew to the 5th highest quarter. In addition, IPO deals sweetened a moribund market with 11 VC-funded companies taken to IPO during 2Q13.

«También en España hemos visto ventas de empresas por importes muy significativos como Endosense del fondo Ysios. Somos optimistas para el sector porque gran parte del dinero de estas ventas volverá al circuito de la financiación del sector salud tal como ha declarado SODENA en el día de hoy» comenta Diego Gutierrez experto en finanzas corporativas en ABRA INVEST.» De hecho el sector de la salud se sitúa en segundo lugar después del de las TICS, tanto en España como en Estados Unidos» apunta Diego Gutierrez.

Top 3: Novo Group, Johnson & Johnson and Novartis

Based on levels of M&A activity, the Denmark-based Novo Group tops the list with more than 50 investments made in health-related companies. Just behind the Novo Group are Swiss-based pharmaceutical giants Johnson & Johnson and Novartis, both of which maintain their private equity arms.

Pharmaceutical companies among the top 10 most active corporate investors across all sectors

Johnson & Johnson Development Corp. y Novartis Venture Funds, se clasifican entre los 10  inversores más activos  como «Corporate Venture Capital» en todos los sectores. Ocho de los 10 son empresas que cotizan en la Bolsa de Valores de Nueva York. «El Ventura capital corporativo está resurfacing como lo hizo en la era dotcom. La tendencia parece seguir en el 2 trimestre 2013 con un crecimiento del 40% en número de CVCs que han intervenido en alguna oepración.» señala Diego Gutierrez.

Lastest news

Webinar | Cómo maximizar el valor de tu empresa antes de vender

INFORMACIÓN IMPORTANTE: La inscripción y participación en los webinars es totalmente anónima para terceros Cómo maximizar el valor de tu empresa antes de vender Maximizar el valor de tu empresa antes de vender es, casi siempre, el trabajo más rentable que puede hacer...

The State of technology M&A in Spain | May 2026 Analysis

El M&A tecnológico en España registró en mayo de 2026 36 operaciones identificadas con un importe agregado conocido de aproximadamente 720,7 millones de euros. La cifra es una referencia mínima: 13 transacciones no hicieron público su importe. El mes combinó...

Notable technology M&A deals in Spain | Analysis: April 2026

The market for the sale and acquisition of technology companies in Spain once again saw particularly brisk activity in April 2026. The month saw significant deals in vertical software, cybersecurity, cloud computing, payments, artificial intelligence, telecommunications...

What does Constellation Software teach us about real value in tech M&A?

An analysis by Diego Gutiérrez Zarza, Partner at Baker Tilly Tech M&A For years, growth was enough to build value in a technology company. That is no longer the case. The market continues to pay a premium for good software companies, but it no longer rewards growth for its own sake...

Strategic Guide: AI and Valuation Multiples in Tech M&A in 2026

An analysis by Diego Gutiérrez Zarza, Partner at Baker Tilly Tech M&A To help you understand the current market for buying and selling technology companies, we have summarised the key points of our latest research in this quick-reference guide. How are...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?

    Request for information

    If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

    Or if you prefer, call us at:

    +34 946 42 41 42